Drs. Cunningham, Dunbar, Garlich, and Schaeffer discuss diagnosing and classifying patients with presbyopia, understanding the mechanism of action of pharmaceutical therapies, and matching patients with the best treatment.
This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Sponsored by 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 125183, is accredited by COPE for continuing education for optometrists. This course is approved for 1.25 hours of CE.
Course #: 82026-GO
Activity #: 125183
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Mark T. Dunbar, OD, FAAO
Director of Optometric Services
Bascom Palmer Eye Institute
University of Miami School of Medicine
Miami, FL
Derek N. Cunningham, OD, FAAO
Co-Founder and President
Sports Vision Pros
Director of Optometry and Clinical Research
Dell Laser Consultants
Austin, TX
Jaclyn Garlich, OD, FAAO
Editor and Founder, 20/20 Glance
Owner, Envision Optometry
Boston, MA
Jack L. Schaeffer, OD, FAAO
Past President and Founder
Chief of Optometry
Schaeffer Eye Center
Birmingham, AL
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan, Carl Zeiss Meditec, Genentech, Reed Exibitions, Regeneron, and Tarsus. Consultant: Allergan, Avellino, Carl Zeiss Meditec, Genentech, Iveric Bio, Orasis Pharmaceuticals, Regeneron, and Visus. Speaker's Bureau: Allergan, Carl Zeiss Meditec, and Regeneron.
Derek N. Cunningham, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra, Bausch + Lomb, Johnson & Johnson Vision, Lumenis, Orasis Pharmaceuticals, RVL, Santen, and Sight Sciences. Speaker's Bureau: Kala Pharmaceuticals and Oyster Point Pharma. Editor: Journal of Sport and Performance Vision.
Jaclyn Garlich, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Aldeyra, Bruder Healthcare, Dompé, Lumenis, Novartis, Orasis Pharmaceuticals, Oyster Point Pharma, Tarsus Pharmaceuticals, and Théa Pharma.
Jack L. Schaeffer, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Speaker's Bureau: Alcon, Allergan, AMO/Abbott, Arctic/Dx, Aton, Bausch + Lomb, Carl Zeiss Meditec, CooperVision, Essilor, Hoya, Optos, Optovue, SARcode Bioscience, TearScience, Valeant, and Vistakon.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Orasis Pharmaceuticals.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
